← Leaderboards
Timothy Vartanian
Beth Israel Deaconess Medical Center
$10,867,825
Attributed
$12,662,740
Total exposure
12
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,662,740 · 12
By mechanism
R01$7,837,148 · 5
P01$2,684,747 · 2
R21$1,814,955 · 4
K02$325,890 · 1
Top collaborators
- Lilyana Amezcua5 shared
- Nancy L Monson5 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsOligodendrogliaNeuronsMultiple SclerosisImmuneInflammatoryMolecularPathway InteractionsMediatingDemyelinationsLesionAxonMyelinBaseReceptorFutureProductionMicrogliaAstrocytesInjuryInflammationSpinal CordGenesCell Death
Grant awards (39)
Immunology of advancing disease among minorities with Multiple Sclerosis$530,415
R01 · FY2025 · NS
Immune Privilege, CNS Autoimmunity, and Clostridium perfringens Epsilon Toxin$662,275
R01 · FY2024 · AI · contact PI
Immunology of advancing disease among minorities with Multiple Sclerosis$519,124
R01 · FY2024 · NS
Immune Privilege, CNS Autoimmunity, and Clostridium perfringens Epsilon Toxin$679,650
R01 · FY2023 · AI · contact PI
Immunology of advancing disease among minorities with Multiple Sclerosis$536,540
R01 · FY2023 · NS
Immunology of advancing disease among minorities with Multiple Sclerosis$537,221
R01 · FY2022 · NS
Damage Associated Molecular Patterns and Regenerative Failure in MS$369,074
R01 · FY2022 · NS · contact PI
Immunology of advancing disease among minorities with Multiple Sclerosis$569,072
R01 · FY2021 · NS
Damage Associated Molecular Patterns and Regenerative Failure in MS$369,109
R01 · FY2021 · NS · contact PI
Determining Enhanced Inflammatory B cell Function in African Americans with MS$211,875
R21 · FY2021 · AI · contact PI
Damage Associated Molecular Patterns and Regenerative Failure in MS$369,144
R01 · FY2020 · NS · contact PI
Determining Enhanced Inflammatory B cell Function in African Americans with MS$254,250
R21 · FY2020 · AI · contact PI
Damage Associated Molecular Patterns and Regenerative Failure in MS$369,178
R01 · FY2019 · NS · contact PI
An Infectious Etiology for Multiple Sclerosis$211,875
R21 · FY2019 · NS · contact PI
Damage Associated Molecular Patterns and Regenerative Failure in MS$369,046
R01 · FY2018 · NS · contact PI
An Infectious Etiology for Multiple Sclerosis$254,250
R21 · FY2018 · NS · contact PI
Functional Link Between Innate Immunity, Oligodendrocyte Development, and Myelina$295,750
R01 · FY2010 · NS · contact PI
Innate Immune Mechanisms of Motor Neuron Injury$212,500
R21 · FY2010 · NS · contact PI
Innate Immunity in the Pathogenesis of PVL$448,079
P01 · FY2009 · NS · contact PI
Functional Link Between Innate Immunity, Oligodendrocyte Development, and Myelina$295,750
R01 · FY2009 · NS · contact PI
Innate Immune Mechanisms of Motor Neuron Injury$255,000
R21 · FY2009 · NS · contact PI
Innate Immunity in the Pathogenesis of PVL$448,079
P01 · FY2008 · NS · contact PI
Innate Immunity in the Pathogenesis of PVL$319,583
P01 · FY2007 · NS · contact PI
Targeting innate immunity to prevent CNS injury in neonatal meningitis$185,705
R21 · FY2007 · NS · contact PI
Innate Immunity in the Pathogenesis of PVL$333,722
P01 · FY2006 · NS · contact PI
Targeting innate immunity to prevent CNS injury in neonatal meningitis$229,500
R21 · FY2006 · NS · contact PI
Innate Immunity in the Pathogenesis of PVL$350,888
P01 · FY2005 · NS
Molecular Basis of Oligodendrocyte Development$323,000
R01 · FY2005 · NS
Molecular Basis of Oligodendrocyte Development$323,000
R01 · FY2004 · NS
Molecular Basis of Oligodendrocyte Development$85,000
R01 · FY2004 · NS
Molecular Basis of Oligodendrocyte Development$323,000
R01 · FY2003 · NS
Molecular Basis of Oligodendrocyte Development$311,800
R01 · FY2002 · NS
Cytokine mediated oligodendrocyte injury$196,099
P01 · FY2002 · NS
NEUREGULINS IN OLIGODENDROCYTE DEVELOPMENT &MYELINATION$99,630
K02 · FY2002 · NS
Cytokine mediated oligodendrocyte injury$196,099
P01 · FY2001 · NS
NEUREGULINS IN OLIGODENDROCYTE DEVELOPMENT &MYELINATION$99,630
K02 · FY2001 · NS
Cytokine mediated oligodendrocyte injury$196,099
P01 · FY2000 · NS
Cytokine mediated oligodendrocyte injury$196,099
P01 · FY2000 · NS
NEUREGULINS IN OLIGODENDROCYTE DEVELOPMENT &MYELINATION$126,630
K02 · FY2000 · NS